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EDITORIAL COMMENT
Is it Time to Measure Fractional
Flow Reserve in All Patients?*
Nico H. J. Pijls, MD, PHD
Eindhoven, Netherlands
The shortcomings of angiography to assess the physiologic
significance of coronary atherosclerosis are well known
(1,2). Particularly in patients with diffuse disease or unstable
coronary syndromes, the angiogram is of little help to
ascertain the potential of an individual stenosis to cause
reversible myocardial ischemia. Waiting for noninvasive
testing such as nuclear stress perfusion scintigraphy (SPS) in
patients admitted for acute chest pain, whether or not true
angina, is often time consuming and prolongs hospital stay.
If signs of reversible ischemia are found at stress testing,
angiography will be performed anyway, and even then
uncertainty quite often persists, especially in the setting of
multivessel disease (3,4). Therefore, the need for a reliable
lesion-specific invasive index to indicate whether a particu-
lar stenosis is responsible for transient ischemia, and con-
sequently should be treated, is indisputable.
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Fractional flow reserve (FFR) is such an index. Fractional
flow reserve is defined as the ratio of maximum blood flow
in a stenotic artery to normal maximum flow in the same
vessel (5,6). Stated another way, maximum flow in the
presence of the stenosis is expressed as a fraction of
maximum flow in the hypothetical case that the epicardial
artery is completely normal. In contrast to most other
invasive indexes, fractional flow reserve has a direct clinical
relevance: for example, FFR of 0.60 means that the maxi-
mum amount of blood (and oxygen) supplying that partic-
ular myocardial distribution only reaches 60% of what it
would be if the respective artery were completely normal.
An increase to 0.90 after coronary intervention indicates
that maximum blood supply has increased now by 50%
(5–8).
The characteristics of FFR have been extensively de-
scribed and validated over recent years. Fractional flow
reserve can be calculated by taking the ratio of mean distal
coronary pressure to aortic pressure during maximum cor-
onary hyperemia. The latter can be achieved by intracoro-
nary adenosine or papaverine administration or by intrave-
nous infusion of adenosine (5–8). Fractional flow reserve
has a uniform normal value of 1 for every patient and every
coronary artery (7–9). In contrast to other invasive indexes,
it is not dependent on changes in heart rate, blood pressure,
or contractility (10); it accounts for the presence of collat-
erals (5,11), and has a sharp threshold value to indicate
inducible ischemia: FFR 0.75 always indicates inducible
ischemia; FFR 0.80 excludes ischemia in 90% of the cases
(6,7,12–14). The “gray zone” is very limited, which is
important for clinical decision making in an individual
patient.
In contrast to some years ago, when wires to measure
coronary pressure were more difficult to handle and had
technical shortcomings, the present pressure wires have
handling characteristics similar to normal guide wires.
Intracoronary pressure measurements are very easy now and
do not significantly prolong the procedure, even when
multiple vessels are interrogated. As shown in several large
studies published recently, FFR can be measured success-
fully in 99% of the arteries, and the measurements are
extremely reproducible (4,15,16). More recently, the prog-
nostic value of FFR measurement post-stenting has been
demonstrated in a large multicenter study in 750 patients.
Normalization of FFR after stent placement (thereby re-
storing normal conductance of the artery) was accompanied
by a restenosis rate of 5% at six-month follow-up, with a
strong inverse correlation between post-stent FFR and
event rate (16).
FFR in unstable coronary syndromes. The usefulness of
FFR in unstable coronary syndromes has been less well
documented to date. In the early phase after myocardial
infarction, severe microvascular impairment (no reflow,
stunning, inflammation) may be present but often improves
over time. The impact of a “residual” epicardial stenosis may
therefore be underestimated in the first days after infarction
(17–19). A low FFR still indicates hemodynamic signifi-
cance of the residual stenosis, but high FFR does not
necessarily exclude this. Yet, it has been shown recently that,
much as in patients with stable coronary artery disease, the
classical 0.75 to 0.80 threshold value could be used from five
days after acute myocardial infarction (19,20).
In patients admitted for unstable angina or non–ST-
segment elevation myocardial infarction (NSTEMI), no
data were available. In this issue of the Journal, Leesar et al.
(21) publish an interesting study to fill this gap. Patients
admitted for unstable angina pectoris, stabilized with med-
ical treatment, were randomly assigned to either invasive
evaluation, including coronary pressure measurement, or
noninvasive evaluation by SPS. The invasive approach with
FFR not only proved to be equally effective in terms of
preventing adverse events after one year and resulted in less
angina at follow-up, but was also associated with a shorter
hospital stay and significant decrease in total costs of
treatment.
It should be emphasized that this study applies only to
those patients with unstable angina/NSTEMI who could be
initially stabilized by medical treatment. It is clear that in
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case of failure of clinical stabilization, urgent angiography is
generally warranted and that in such cases no pressure
measurement or other additional information is necessary to
justify percutaneous coronary intervention (PCI) of the
culprit lesion. Even in those cases, after treatment of the
culprit lesion, FFR analysis of other stenoses (when present)
can be helpful and indicate the need for additional treat-
ment, preventing repeated invasive procedures later on and
thereby reducing costs even more, as will be outlined.
The way in which Leesar et al. (21) performed their
cost-efficiency analysis is straightforward and understand-
able. Rather than assuming complex models with multiple
theoretical assumptions and extrapolations, the true costs of
the hospital stay and investigations were calculated (21).
More complex and extensive coronary disease. The study
by Leesar et al. (21) was restricted by design to patients with
single-vessel disease. Thus, the only question to be solved
was if the residual stenosis was still responsible for inducible
ischemia and should be treated. Yet, this approach of
invasive functional assessment is even more useful (and
probably even more cost-efficient) in patients with unstable
angina and multivessel disease. In such patients (unfortu-
nately more common in today’s catheterization laboratory),
other stenoses can be evaluated as well and treated conse-
quently. In the case of diffuse coronary atherosclerosis or
multivessel disease, it is often impossible both by nuclear
stress testing and by angiography to indicate which of
several stenoses may be culprit (4). Systematic segmental
analysis of the coronary arteries by pressure pull-back
recording has shown that the real culprit spots or segments
are often different from those expected by angiography
(9,16,22). Treatment based upon the angiogram alone is
often incomplete or performed at the wrong location,
necessitating further interventions in the short term. Iron-
ically, these early reinterventions are often attributed to
restenosis, rapid progression of disease, or bad luck, whereas
they may actually relate to a hemodynamically significant
stenosis that remained undetected at initial angiography.
To make a pressure pull-back recording, the sensor-
tipped guide wire is placed in the distal coronary artery,
steady-state maximum hyperemia is induced, and the sensor
is pulled back slowly under fluoroscopy while the pressure
recording is watched. The spatial resolution of this method
is unsurpassed by any other invasive or noninvasive meth-
odology. A correct selection of segments to be stented is
obtained in minutes and delayed discharge from the hospital
because of additional noninvasive testing or expensive re-
peated hospitalization later on can be avoided. The savings
demonstrated in the study by Leesar et al. (21) in patients
with single-vessel disease are likely to be even larger in such
patients with more complex disease.
With the introduction of drug-eluting stents, many more
patients with complex coronary disease will probably present
in our cathlabs in the next years (23). This underscores the
importance of a simple, swift, and safe method to determine
the hemodynamics of each individual stenosis in the cath-
eterization laboratory.
Consequences for health care. More important than the
savings demonstrated by Leesar et al are the implications for
patient care. It is not acceptable to treat patients in a
suboptimum way simply because we do not understand
physiology or just do not want to spend a few more minutes
to acquire fundamental information. In an era of major
breakthroughs in diagnosis (24–26) and treatment of cor-
onary artery disease (23), it can be anticipated that patients
with even more complex forms of coronary artherosclerosis
will be considered for PCI. A more refined and individual-
ized understanding of their disease and a more appropriate
selection of the epicardial lesions to be treated will be
paramount not only for patient care but also to keep health
care affordable (27–29). Therefore, a simple, reliable, and
relatively cheap technology such as coronary pressure mea-
surement, although not indicated in all patients, should
become standard in at least the majority.
Reprint requests and correspondence: Dr. Nico H. J. Pijls,
Department of Cardiology, Catharina Hospital, P.O. Box 1350,
5602 ZA Eindhoven, Netherlands. E-mail: cardiologie.catharina.
zks@wxs.nl.
REFERENCES
1. Nissen SE, Gurley JC. Assessment of the functional significance of
coronary stenoses. Circulation 1990;81:1431–5.
2. Bartunek J, Sys SU, Heyndrickx GR, et al. Quantitative coronary
angiography in predicting functional significance of stenoses in an
unselected patient cohort. J Am Coll Cardiol 1995;26:328–34.
3. Travin MI, Katz MS, Moulton AM, et al. Accuracy of dipyridamole
SPECT imaging in identifying individual coronary stenoses and
multivessel disease in women versus men. J Nucl Cardiol 2000;7:213–
20.
4. Botman KJ, Pijls NHJ, Bech GJW, et al. Percutaneous coronary
intervention or bypass surgery in multivessel coronary disease? A
tailored approach based on coronary pressure measurement. Z Kardiol
2003. In press.
5. Pijls NHJ, Van Son JAM, Kirkeeide RL, et al. Experimental basis of
determining maximum coronary, myocardial, and collateral blood flow
by pressure measurements for assessing functional stenosis severity
before and after percutaneous transluminal coronary angioplasty.
Circulation 1993;87:1354–67.
6. Pijls NHJ, De Bruyne B, Peels K, et al. Measurement of fractional flow
reserve to assess the functional severity of coronary artery stenoses.
N Engl J Med 1996;334:1703–8.
7. Pijls NHJ, Van Gelder B, Van der Voort P, et al. Fractional flow
reserve. A useful index to evaluate the influence of an epicardial
coronary stenosis on myocardial blood flow. Circulation 1995;92:
3183–93.
8. Lederman SJ, Menegus MA, Greenberg MA. Fractional flow reserve.
ACC Curr J Rev 1977;2:34–5.
9. De Bruyne B, Hersbach F, Pijls NHJ, et al. Abnormal epicardial
coronary resistance in patients with diffuse atherosclerosis but “normal”
coronary angiography. Circulation 2001;104:2401–6.
10. De Bruyne B, Bartunek J, Sys SU, et al. Simultaneous coronary
pressure and flow velocity measurements in humans: feasibility, repro-
ducibility, and hemodynamic dependence of coronary flow velocity
reserve, hyperemic flow versus pressure slope index, and fractional flow
reserve. Circulation 1996;94:1843–9.
11. Matsuo H, Watanabe S, Kadosaki T, et al. Validation of collateral
fractional flow reserve by myocardial perfusion imaging. Circulation
2002;105:1060–5.
1123JACC Vol. 41, No. 7, 2003 Pijls
April 2, 2003:1122–4 Editorial Comment
12. Abe M, Tomiyama H, Yoshida H, et al. Diastolic fractional flow
reserve to assess the functional severity of moderate coronary artery
stenoses. Circulation 2000;102:2365–70.
13. Kern MJ. Coronary physiology revisited. Practical insights from the
catheterization laboratory. Circulation 2000;101:1344–51.
14. Chamuleau SAJ, Meuwissen M, Van Eck-Smit BLF, et al. Fractional
flow reserve, absolute and relative coronary blood flow velocity reserve
in relation to the results of Tc-99m sestamibi SPECT in patients with
two-vessel coronary artery disease. J Am Coll Cardiol 2001;37:1316–
22.
15. Bech GJW, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve to
determine the appropriateness of angioplasty in de moderate coronary
stenosis. A randomized trial. Circulation 2001;103:2928–34.
16. FFR Post-stent Registry Investigators. Coronary pressure measure-
ment after stenting predicts adverse events at follow-up. A multicenter
registry. Circulation 2002;105:2950–4.
17. Wilson RF. Looks aren’t everything. FFR B4 U PTCA. Circulation
2001;103:2873–5.
18. Claeys MJ, Bosmans JM, Hendrix J, et al. Reliability of fractional flow
reserve measurements in patients with associated microvascular dys-
function. Cathet Cardiovasc Intervent 2001;54:427–34.
19. De Bruyne B, Pijls NHJ, Bartunek J, et al. Fractional flow reserve in
patients with prior myocardial infarction. Circulation 2001;104:157–
62.
20. Lee CW, Park SW, Cho GY, et al. Pressure-derived fractional
collateral blood flow: a primary determinant of left ventricular recovery
after reperfused acute myocardial infarction. J Am Coll Cardiol
2000;35:949–55.
21. Leesar MA, Abdul-Baki T, Akkus NI, Sharma A, Kannan T, Bolli R.
Use of fractional flow reserve versus stress perfusion scintigraphy after
unstable angina: effect on duration of hospitalization, cost, procedural
characteristics, and clinical outcome. J Am Coll Cardiol 2003;41:
1115–21.
22. Pijls NHJ, De Bruyne B, Bech GJW, et al. Coronary pressure
measurement to assess the hemodynamic significance of serial stenoses
within one coronary artery. Validation in humans. Circulation 2000;
102:2371–7.
23. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison
of sirolimces-eluting stent with a standard stent for coronary revascu-
larization. N Engl J Med 2002;36:1773–80.
24. Nieman K, Cademartizi F, Lemos P, et al. Reliable non-invasive
coronary angiography with fast submillimeter multislice spiral com-
puted tomography. Circulation 2002;106:2051–4.
25. De Bruyne B, Pijls NHJ, Smith L, et al. Coronary thermodilution to
assess flow reserve. Experimental validation. Circulation 2001;104:
2003–6.
26. Pijls NHJ, De Bruyne B, Smith L, et al. Coronary thermodilution to
assess flow reserve. Validation in humans. Circulation 2002;105:
2482–6.
27. Klein LW, Schaer GL. If invasive functional testing is so great, why
aren’t we doing it routinely? Cathet Cardiovasc Intervent 2001;53:39–
40.
28. Hodgson JMcB. FFR for all. Cathet Cardiovasc Intervent 2001;54:
435–6.
29. Habib S, Ragosta M, Beller G. Coronary collaterals, stenoses, and
stents. J Am Coll Cardiol 2002;40:1551–4.
1124 Pijls JACC Vol. 41, No. 7, 2003
Editorial Comment April 2, 2003:1122–4
